Ocugen said its ArMaDa Phase 2 study is advancing toward Phase 3 for OCU410, its gene therapy candidate for geographic atrophy. The move expands its push in oph

Ocugen said its ArMaDa Phase 2 study is advancing toward Phase 3 for OCU410, its gene therapy candidate for geographic atrophy. The move expands its push in ophthalmic gene therapy for a severe dry AMD subtype affecting an estimated 2–3 million people.